Combination therapy for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial is testing a combination of treatments for liver cancer that cannot be removed by surgery. It combines a targeted therapy pill (lenvatinib), an immunotherapy that boosts your immune system (PD-1 blocker), a procedure that destroys tumors with heat or cold (ablation), and a chemo procedure that delivers medicine directly to the liver (TACE). The goal is to see if this mix is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have a type of liver cancer called hepatocellular carcinoma that cannot be removed by surgery.
- Your cancer must have at least one untreated tumor larger than 5 cm that can be treated with ablation (a procedure that destroys tumors using heat or cold).
- You should be generally active (able to do light work or care for yourself) and expected to live more than 3 months.
- If you've had previous cancer treatments, your disease must have stayed the same or grown after those treatments.
- Your liver function must be reasonably good (Child-Pugh score 7 or lower).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment that uses heat (ablation) and other therapies to destroy liver tumors. It's for people who cannot have surgery or choose not to, and whose tumor is a specific size.
This trial is testing a new combination therapy for liver cancer that cannot be surgically removed. It uses an immune-boosting drug (atezolizumab), a drug that blocks blood flow to tumors (bevacizumab), and a type of chemotherapy that is delivered directly into the liver artery (HAIC). This combination may help shrink liver tumors and improve outcomes.
This trial tests a heat-based treatment for liver cancer tumors that uses multiple methods to destroy cancer cells. It may help people with liver tumors that haven't spread and who are healthy enough for treatment.
This study tests a combined treatment using heat (thermal therapy), targeted drugs, and immunotherapy to shrink liver tumors that cannot be surgically removed. It aims to find out if this combination is safe and effective for people with intermediate or advanced liver cancer.
This trial tests a combination of a procedure that delivers chemotherapy directly to the liver tumor (called TACE) with an oral targeted therapy drug (lenvatinib) for people with liver cancer that cannot be removed with surgery. The goal is to see if this combination can shrink tumors more effectively than TACE alone.
This trial tests a combination of a focused radiation beam (SBRT) plus a pill that helps stop tumor blood vessel growth (lenvatinib) and a procedure that blocks blood flow to the tumor (TACE) for people with advanced liver cancer that has not yet spread outside the liver. The goal is to see if this triple therapy can improve outcomes without prior treatment.
Hear when a new Neoplasms, Glandular and Epithelial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.